Gunderson Thomas James
CIK: 0001708144
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Merit Medical Systems sets Q3 2026 earnings date. Merit Medical Systems announced it will report its third-quarter 2026 results on October 29, 2026. This upcoming earnings date is the primary catalyst for the stock, as investors await fresh financial updates. The company is currently trading within its 52-week range, with an average analyst target price of $101.45.
Transaction History
| TMDX | ▲ Buy | Option Exercise | 19,285 | $43K | 6/15/2026 | View on chart |
| TMDX | ▼ Sell | Open Market | 9,624 | $722K | 6/15/2026 | View on chart |
| TMDX | ▲ Buy | Grant | 2,922 | $0 | 5/20/2026 | View on chart |
| MMSI | ▲ Buy | Option Exercise | 13,750 | $717K | 5/20/2026 | View on chart |
| MMSI | ▲ Buy | Option Exercise | 7,500 | $391K | 5/20/2026 | View on chart |
| MMSI | ▲ Buy | Grant | 3,457 | $0 | 5/18/2026 | View on chart |
| TMDX | ▲ Buy | Grant | 2,134 | $0 | 5/22/2025 | View on chart |
| MMSI | ▲ Buy | Grant | 2,152 | $0 | 5/15/2025 | View on chart |
| MMSI | ▲ Buy | Option Exercise | 25,000 | $1.3M | 2/28/2025 | View on chart |
| MMSI | ▼ Sell | Tax Withholding | 12,806 | $1.3M | 2/28/2025 | View on chart |
| TMDX | ▲ Buy | Grant | 732 | $0 | 5/23/2024 | View on chart |
| MMSI | ▲ Buy | Grant | 2,431 | $0 | 5/16/2024 | View on chart |
| MMSI | ▲ Buy | Option Exercise | 25,000 | $860K | 3/4/2024 | View on chart |
| MMSI | ▼ Sell | Open Market | 18,157 | $1.4M | 3/4/2024 | View on chart |
| TMDX | ▲ Buy | Grant | 1,193 | $0 | 5/25/2023 | View on chart |
| MMSI | ▲ Buy | Grant | 2,262 | $0 | 5/18/2023 | View on chart |
| MMSI | ▲ Buy | Grant | 3,050 | $0 | 5/24/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
TransMedics Group Faces Analyst Sentiment Shift
Barclays has begun covering TransMedics Group, giving it an overweight rating and a $120 price target. At the same time, Intel downgraded the company while Marvell upgraded it, showing mixed analyst views. These moves may influence how investors view the stock, especially as it trades near its 52‑week range. The company remains in a neutral technical zone with an RSI of 45 and support at $74.62.
TransMedics Group Faces Analyst Sentiment Shift. Barclays has begun covering TransMedics Group, giving it an overweight rating and a $120 price target. At the same time, Intel downgraded the company while Marvell upgraded it, showing mixed analyst views. These moves may influence how investors view the stock, especially as it trades near its 52‑week range. The company remains in a neutral technical zone with an RSI of 45 and support at $74.62.